Log in

OTCMKTS:DSNKY - DAIICHI SANKYO/S Stock Price, Forecast & News

$68.22
+0.64 (+0.95 %)
(As of 12/15/2019 04:00 PM ET)
Today's Range
$67.60
Now: $68.22
$69.00
50-Day Range
$61.21
MA: $63.56
$67.59
52-Week Range
$30.00
Now: $68.22
$69.00
Volume3,744 shs
Average Volume11,418 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, and markets pharmaceutical products worldwide. The company offers prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone compilations; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine and donepezil for treating Alzheimer's disease; laninamivir for anti-influenza treatment; and silodosin for treating dysuria. It also provides olmesartan and Telmisartan antihypertensive agents; levofloxacin, an antibacterial agent; pravastatin and Rosuvastatin antihyperlipidemic agents; iohexol to enhance the visibility of diagnostic X-ray imaging; loxoprofen, an anti-inflammatory analgesic; and naloxegol for opioid-induced constipation treatment. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a cold remedy; Loxonin S, an anti-inflammatory analgesic; Transino for treating melisma/alleviating spots, freckles, and pigmentation; Minon, a moisturizing cleanser; and Clean Dental, an oral care product. Additionally, the company offers Influenza HA Vaccine; Rotarix Oral Liquid, a vaccine for prevention of rotavirus; ActHIB, a haemophilus influenzae type b vaccine; Live Attenuated Measles-Rubella Combined Vaccine; and Squarekids, a vaccine for the prevention of pertussis, diphtheria, tetanus, and poliomyelitis. It also offers pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration agreements with Roche for the development of a HER2 diagnostic test; Sarah Cannon Research Institute to develop novel cancer therapies; and Integral Molecular, Inc. The company was founded in 1899 and is headquartered in Tokyo, Japan.

Industry, Sector and Symbol

Industry Pharmaceuticals: Other
Sub-IndustryN/A
SectorHealth Technology
Current SymbolOTCMKTS:DSNKY
CUSIPN/A
CIKN/A
Phone(136) 225-1111

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees14,446
Next Earnings DateN/A
OptionableNot Optionable

Receive DSNKY News and Ratings via Email

Sign-up to receive the latest news and ratings for DSNKY and its competitors with MarketBeat's FREE daily newsletter.


DAIICHI SANKYO/S (OTCMKTS:DSNKY) Frequently Asked Questions

What is DAIICHI SANKYO/S's stock symbol?

DAIICHI SANKYO/S trades on the OTCMKTS under the ticker symbol "DSNKY."

What is the consensus analysts' recommendation for DAIICHI SANKYO/S?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DAIICHI SANKYO/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DAIICHI SANKYO/S.

Has DAIICHI SANKYO/S been receiving favorable news coverage?

News stories about DSNKY stock have been trending neutral on Sunday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. DAIICHI SANKYO/S earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for DAIICHI SANKYO/S.

Who are some of DAIICHI SANKYO/S's key competitors?

What other stocks do shareholders of DAIICHI SANKYO/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DAIICHI SANKYO/S investors own include VOLVO AB/ADR (VLVLY), Scorpio Tankers (STNG), Interpublic Group of Companies (IPG), Ensco Rowan (ESV), MeiraGTx (MGTX), Cincinnati Financial (CINF) and Align Technology (ALGN).

Who are DAIICHI SANKYO/S's key executives?

DAIICHI SANKYO/S's management team includes the folowing people:
  • Mr. Joji Nakayama, Chairman & Global CEO (Age 69)
  • Mr. Sunao Manabe, Pres, COO & Representative Director (Age 65)
  • Mr. Toshiaki Sai, CFO, Exec. VP, Head of Corp. Strategy & Management Division and Representative Director
  • Mr. Junichi Onuma, Sr. Director of IR Group
  • Mr. Yoshihiro Aoyagi, Head of Corp. Affairs Division, Exec. Officer & Gen. Counsel

How do I buy shares of DAIICHI SANKYO/S?

Shares of DSNKY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is DAIICHI SANKYO/S's stock price today?

One share of DSNKY stock can currently be purchased for approximately $68.22.

What is DAIICHI SANKYO/S's official website?

The official website for DAIICHI SANKYO/S is http://www.daiichisankyo.com/.

How can I contact DAIICHI SANKYO/S?

The company can be reached via phone at (136) 225-1111.


MarketBeat Community Rating for DAIICHI SANKYO/S (OTCMKTS DSNKY)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  36 (Vote Outperform)
Underperform Votes:  47 (Vote Underperform)
Total Votes:  83
MarketBeat's community ratings are surveys of what our community members think about DAIICHI SANKYO/S and other stocks. Vote "Outperform" if you believe DSNKY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DSNKY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2019 by MarketBeat.com Staff

Featured Article: Capital Gains Distribution

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel